摘要
目的 探讨华蟾素联合呋喹替尼三线治疗晚期结直肠癌患者对免疫功能、肿瘤标志物及血管生成的影响。方法 选取2022年12月至2023年11月内蒙古医科大学附属医院接受三线治疗的58例晚期结直肠癌患者,经随机数字表法分为对照组(呋喹替尼治疗,29例)和观察组(联合华蟾素胶囊,29例)。比较两组治疗前后的免疫功能、肿瘤标志物及血管新生因子的水平变化情况。结果 在临床获益率(CBR)方面,观察组较对照组更高(χ^(2)=4.858,P<0.05)。治疗后,两组CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)均较治疗前升高(均P<0.05),且观察组CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)[分别为(39.97±7.00)%、(24.42±0.97)%、(1.61±0.37)]高于对照组[分别为(33.23±6.13)%、(23.34±0.85)%、(1.43±0.30)](t=3.900、4.509、2.035,均P<0.05);治疗后,两组糖类抗原125(CA125)、糖类抗原19-9(CA19-9)、癌胚抗原(CEA)均较治疗前降低(均P<0.05),且观察组CA125、CA19-9及CEA[分别为(32.22±5.23)μg·m L^(-1)、(28.59±4.03)μg·m L^(-1)、(16.12±2.46)μg·m L^(-1)]低于对照组[分别为(41.95±6.20)μg·m L^(-1)、(36.19±5.06)μg·m L^(-1)、(23.77±4.01)μg·m L^(-1)](t=6.460、6.327、8.757,均P<0.05);治疗后,两组血管内皮生长因子(VEGF)、低氧诱导因子-1α(HIF-1α)、转化生长因子-β1(TGF-β1)均较治疗前降低(均P<0.05),且观察组VEGF、HIF-1α、TGF-β1[分别为(550.96±80.33) pg·m L^(-1)、(41.55±5.12) ng·L^(-1)、(13.19±2.98) pg·m L^(-1)]低于对照组[分别为(600.44±83.22) pg·m L^(-1)、(58.77±6.60) ng·L^(-1)、(18.76±3.77) pg·m L^(-1)](t=2.304、11.102、6.242,均P<0.05)。结论 华蟾素胶囊联合呋喹替尼三线治疗晚期结肠癌能够下调患者肿瘤标志物CA125、CA19-9及CEA,调节患者免疫功能、减少肿瘤血管生成。
Objective To investigate the effect of cinobufotalin combined with fuquintinib on immune function,tumor markers and angiogenesis in patients with advanced colorectal cancer receiving the third-line treatment by combined use of the two drugs.Methods A total of 58 patients with advanced colorectal cancer undergoing the third-line treatment in the Affiliated Hospital of Inner Mongolia Medical University from December 2022 to November 2023 were randomly divided into a control group(treated with fuquintinib,n=29)and an observation group(treated with fuquintinib in combination with cinobufotalin capsules,n=29).The changes in immune function,tumor markers and angiogenic factors before and after treatment were compared between the two groups.Results After treatment,the clinical benefit rate(CBR)was significantly higher in the observation group than in the control(χ^(2)=4.858,P<0.05).The levels of CD4^(+),CD8^(+)and CD4^(+)/CD8^(+)in both groups were higher after than before the treatment(P<0.05).Moreover,they were(39.97±7.00)%,(24.42±0.97)%and(1.61±0.37)in the observation group,which were higher than those in the control((33.23±6.13)%,(23.34±0.85)%and(1.43±0.30))(t=3.900,4.509,2.035,all P<0.05).The levels of CA125,CA19-9 and CEA were decreased in both groups after treatment(all P<0.05),and they were significantly lower in the observation group than in the control((32.22±5.23)μg·mL^(-1) vs(41.95±6.20)μg·mL^(-1),(28.59±4.03)μg·mL^(-1) vs(36.19±5.06)μg·mL^(-1),(16.12±2.46)μg·mL^(-1) vs(23.77±4.01)μg·mL^(-1),t=6.460,6.327,8.757,all P<0.05).Meanwhile,the levels of VEGF,HIF-1αand TGF-β1 were decreased in both groups after treatment(all P<0.05),and they were lower in the observation group than in the control((550.96±80.33)pg·mL^(-1) vs(600.44±83.22)pg·mL^(-1),(41.55±5.12)ng·L^(-1) vs(58.77±6.60)ng·L^(-1),(13.19±2.98)pg·mL^(-1) vs(18.76±3.77)pg·mL^(-1),t=2.304,11.102,6.242,all P<0.05).Conclusion Cinobufotalin capsules combined with fuquitinib for the third-line treatment of advanced colorec
作者
赵海燕
王莉
王华
Zhao Hai-yan;Wang Li;Wang Hua(Department of Oncology,the Affiliated Hospital of Inner Mongolia Medical University,Hohhot 010000,China;the First Clinical College,Inner Mongolia Medical University,Hohhot 010000,China;Department of Gastroenterology,the Affiliated Hospital of Inner Mongolia Medical University,Hohhot 010000,China)
出处
《中国药物应用与监测》
CAS
2024年第4期359-363,共5页
Chinese Journal of Drug Application and Monitoring
基金
内蒙古自治区自然科学基金项目(2021MS08028)。
